NRG-GY027

Open to Accrual

Return to Protocol Table

NRG-GY027: PHASE I/IB SAFETY AND PHARMACODYNAMIC STUDY OF NEOADJUVANT (NACT) PACLITAXEL AND CARBOPLATIN WITH IPATASERTIB AS INITIAL THERAPY OF OVARIAN CANCER PTMA 100805

Principal Investigator

Katherine Fuh, MD, PhD

Status

Open to Accrual

Date Opened To Accrual

June 27 2022

Disease Site

Gynecologic [GY]

Ovarian

Phase

Developmental Therapeutics

Primary Objective

To estimate the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of ipatasertib in combination with paclitaxel and carboplatin as neoadjuvant chemotherapy for ovarian cancer. Primary objectives also include determining the feasibility of the treatment regimen once the MTD is estimated.

Patient Population

Patients with pathologically proven diagnosis of ovarian cancer: high grade serous and endometroid adenocarcinoma, grade 3 are eligible.

Target Accrual

Forms

Study Memos

Safety Reports

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.